Emerging Tools for Alzheimer's Disease

Emerging Tools for Alzheimer's Disease

Report Scope:

The report provides an overview of AD, and the current diagnostic methods. The report explains the need for emerging tools for the early detection of the disease. Tools that have been approved are discussed, as well as tools in the development phase. The report does not include therapeutics approved or in the pipeline for AD.

The report covers the global market for emerging tools with a look at the regional markets of North America, Europe and Emerging Markets.

The report provides a detailed analysis of the current and future global market for emerging tools. Industry growth drivers, restraints and opportunities are also discussed. The report also provides a look at the competitive landscape, profiles of companies developing tools for the early detection of AD, and the impact of COVID-19 on the market.

Report Includes:

An overview of the global market for emerging tools for the early detection of Alzheimer’s disease

Estimation of the market size and analyses of global market trends, with data from 2020 to 2022, estimates for 2023 with projections of compound annual growth rates (CAGRs) through 2028

Highlights of the current and future market potential and quantification of market based on type and region

Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast

Detailed analysis of the regulatory framework and policies and product pipeline of the industry

Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis

Companies Mentioned

AltPep
Araclon Biotech
C2N DIAGNOSTICS LLC
Cognoptix
Diadem Spa
F. HOFFMANN-LA ROCHE AG (ROCHE)
FUJIREBIO DIAGNOSTICS
QUANTERIX CORP.
QUEST DIAGNOSTICS INC.
SYSMEX CORP.